Compare Cytokinetics Inc (CYTK) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Cytokinetics Inc trades at $62.1 (market cap $8.62B), while Vanguard Short Term Corporate Bond ETF trades at $77.28 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 6× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| CYTK | VCSH | |
|---|---|---|
Market Cap | $8.62B | $51.90B |
Volume | 2,594,626 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $87.26 | $80.20 |
52-Week Low | $54.76 | $77.03 |
Typical Hold Time | 19 Days | 52 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $77.27 with a slight 0.08% daily gain. Technical indicators show a bearish trend from moving averages, though oscillators are neutral. The ETF offers a competitive yield and low expense ratio, but faces headwinds from tight credit spreads and a cautious market outlook. Recent news highlights its role as a stable income alternative to CDs or stable value funds, with institutional activity showing mixed positioning.
The outlook for VCSH is neutral with limited upside due to unattractive entry points and constrained credit spreads. Its short duration minimizes interest rate risk, but yield advantages over peers may narrow. Key risks include corporate credit deterioration and Fed policy shifts. Investors seeking short-term, high-quality bond exposure may find value, but current levels offer modest total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
